Tls Beta Pte. Ltd. - Net Worth and Insider Trading
Tls Beta Pte. Ltd. Net Worth
The estimated net worth of Tls Beta Pte. Ltd. is at least $287 Million dollars as of 2025-05-10. Tls Beta Pte. Ltd. is the of Ocumension Therapeutics and owns about 54,169,400 shares of Ocumension Therapeutics (HKSE:01477) stock worth over $287 Million. Details can be seen in Tls Beta Pte. Ltd.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Tls Beta Pte. Ltd. has not made any transactions after 2020-07-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Tls Beta Pte. Ltd.
Tls Beta Pte. Ltd. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Tls Beta Pte. Ltd. owns 1 companies in total, including Ocumension Therapeutics (HKSE:01477) .
Click here to see the complete history of Tls Beta Pte. Ltd.’s form 4 insider trades.
Insider Ownership Summary of Tls Beta Pte. Ltd.
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| HKSE:01477 | Ocumension Therapeutics | 2020-07-10 |
Tls Beta Pte. Ltd. Latest Holdings Summary
Tls Beta Pte. Ltd. currently owns a total of 1 stock. Tls Beta Pte. Ltd. owns 54,169,400 shares of Ocumension Therapeutics (HKSE:01477) as of July 10, 2020, with a value of $287 Million.
Latest Holdings of Tls Beta Pte. Ltd.
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| HKSE:01477 | Ocumension Therapeutics | 2020-07-10 | 54,169,400 | 5.29 | 286,556,126 |
Holding Weightings of Tls Beta Pte. Ltd.
Tls Beta Pte. Ltd. Form 4 Trading Tracker
According to the SEC Form 4 filings, Tls Beta Pte. Ltd. has made a total of 1 transactions in Ocumension Therapeutics (HKSE:01477) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Ocumension Therapeutics is the sale of 0 shares on July 10, 2020, which brought Tls Beta Pte. Ltd. around $0.
Insider Trading History of Tls Beta Pte. Ltd.
- 1
Tls Beta Pte. Ltd. Trading Performance
Tls Beta Pte. Ltd. Ownership Network
Ownership Network List of Tls Beta Pte. Ltd.
Ownership Network Relation of Tls Beta Pte. Ltd.
Tls Beta Pte. Ltd. Owned Company Details
What does Ocumension Therapeutics do?
Who are the key executives at Ocumension Therapeutics?
Tls Beta Pte. Ltd. is the of Ocumension Therapeutics. Other key executives at Ocumension Therapeutics include 2101 Beneficial owner Liu Ye , 2101 Beneficial owner 6 Dimensions Capital, L.P. , and 2201 Interest of corporation controlled by you ZHANG Qiping .
Ocumension Therapeutics (HKSE:01477) Insider Trades Summary
Over the past 18 months, Tls Beta Pte. Ltd. made no insider transaction in Ocumension Therapeutics (HKSE:01477). Other recent insider transactions involving Ocumension Therapeutics (HKSE:01477) include a net sale of 0 shares made by Liu Ye , a net sale of 3,800,000 shares made by Temasek Holdings (private) Limited , and a net purchase of 150,000 shares made by Boyu Capital Group Holdings Ltd .
In summary, during the past 3 months, insiders sold 0 shares of Ocumension Therapeutics (HKSE:01477) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,800,000 shares of Ocumension Therapeutics (HKSE:01477) were sold and 150,000 shares were bought by its insiders, resulting in a net sale of 3,650,000 shares.
Ocumension Therapeutics (HKSE:01477)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ocumension Therapeutics Insider Transactions
Tls Beta Pte. Ltd. Mailing Address
Above is the net worth, insider trading, and ownership report for Tls Beta Pte. Ltd.. Currently GuruFocus does not have mailing address information for Tls Beta Pte. Ltd..
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
